- Home
- NMCO vs VNDA Comparison
NMCO vs VNDA Comparison
Compare NMCO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMCO | VNDA |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 560.1M | 474.0M |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | NMCO | VNDA |
|---|---|---|
| Price | $10.58 | $8.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 141.4K | ★ 3.6M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.50 |
| Revenue Next Year | N/A | $38.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $9.69 | $3.81 |
| 52 Week High | $11.20 | $9.60 |
Technical Indicators
Market Signals| Indicator | NMCO | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 37.74 | 59.84 |
| Support Level | $10.44 | $4.25 |
| Resistance Level | $10.67 | $9.35 |
| Average True Range (ATR) | 0.09 | 0.56 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 15.12 | 86.31 |
Price Performance
Historical ComparisonAbout NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.